26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
16 December 2024 - BasileaBasilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesCeftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…read more >>
25 November 2024 - Centauri Therapeutics LtdCentauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives“We are excited to have support from PACE as we progress the development of our molecules in anti-infectives, and de-risk…read more >>
21 November 2024 - Debiopharm InternationalCARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae InfectionsNow more than ever, new antibiotics are needed to avoid serious public health consequences caused by this infection.read more >>
13 November 2024 - AktheliaAkthelia Pharmaceuticals featured in Icelandic newspaper ViðskiptablaðiðThe article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring…read more >>
04 November 2024 - PHAXIAMPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.This FDA IND clearance is a major recognition of our therapeutic approach and of our whole platform. This is a…read more >>
30 October 2024 - Thioredoxin Systems ABTXN Systems Raises SEK 25 Million Series A to Advance First-in-Class AntibioticWith its novel mechanism of action on a new target, and extensive testing that has demonstrated its effectiveness against a…read more >>
05 May 2020Citizen’s engagement & multi stakeholder’s action to tackle antimicrobial resistance and sustain EU progressONE health approach MULTIPLE answers: Citizen’s engagement & multi stakeholder’s action to tackle antimicrobial resistance and sustain EU progressread more >>
28 April 2020REVIVE Webinar: Inhaled antimicrobials: Do we get the drug to the bug?In this webinar, Harm Tiddens will discuss the relation between structural and functional abnormalities of the lung and how this…read more >>
28 April 2020COVID-19 human challenge trials – what will be the regulatory considerations?The objective of this webinar (45mn presentation / 15mn Q&A) is to explore the potential of CHIM, COVID-19 regulatory considerations,…read more >>
26 March 2020AMR Insights Seminar: Driving Behavioural Change to combat AMRThe Seminar Driving Behavioural Change to combat AMR allows experts from within and outside Europe to give their opinion on…read more >>
23 March 2020BIO-Europe, 14th International Partnering ConferenceBIO-Europe Spring 2020 will now be delivered virtually in light of the increasing travel restrictions worldwide due to the ongoing…read more >>
22 March 2020Europe CEO – The Perfect Prelude to PartneringEurope CEO is an invitation-only, off-the-record forum that brings together the global leaders in the biopharma community to network and…read more >>
27 February 2020REVIVE Webinar: PK/PD murine infection models: Focus on study elements, variability, and interpretation of resultsTopics discussed will include: - Understanding and embracing the inherent variability in many components of the murine model. - Demonstrating…read more >>
27 February 2020GARDP webinar: PK/PD murine infection models: Focus on study elements, variability, and interpretation of resultsTopics discussed will include: - Understanding and embracing the inherent variability in many components of the murine model - Demonstrating…read more >>
04 February 2020GARDP webinar: Non-traditional antibacterial therapeutic options and challengesIn this webinar, the following aspects will be presented: - Discovery and early development of “non-traditional” antibacterial approaches is a…read more >>
